196440

Batimastat

≥98% (HPLC), solid, Matrix metalloproteinase inhibitor, Calbiochem

• Sinônimo(s): Batimastat, (4-N-Hydroxyamino)-2 R-isobutyl-3 S-(thienylthiomethyl)succinyl)-L-phenylalanine-N-methylamide, BB-94, (4-N-Hydroxyamino)-2R-isobutyl-3S-(thienylthiomethyl)succinyl)-L-phenylalanine-N-methylamide, BB-94
• Fórmula empírica (Notação de Hill): C₂₃H₃₁N₃O₄S₂
• Número CAS: 130370-60-4
• Peso molecular: 477.64
• Número MDL: MFCD00866533
• Código UNSPSC: 12352200
• NACRES: NA.77

Propriedades

• Nome do produto: Batimastat, Batimastat primarily used in Inhibition.
• Nível de qualidade: 100
• Ensaio: ≥98% (HPLC)
• Formulário: solid
• fabricante/nome comercial: Calbiochem^®
• condição de armazenamento: OK to freeze; protect from light
• cor: off-white
• solubilidade: DMSO: 50 mg/mL
• Condições de expedição: ambient
• temperatura de armazenamento: 2-8°C
• InChI: 1S/C23H31N3O4S2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11,15,17-19,30H,12-14H2,1-3H3,(H,24,29)(H,25,27)(H,26,28)/t17-,18+,19+/m1/s1
• chave InChI: XFILPEOLDIKJHX-QYZOEREBSA-N

Descrição

Descrição geral

A Marimastat (Cat. No. 444289) type of peptidyl hydroxamate-based inhibitor that potently inhibits a broad-spectrum of metalloproteinases, including MMP-1, MMP-2, MMP-3/stromelysin, MMP-7/matrilysin, MMP-9, ΔMT1 (MMP-14 without TM domain), ADAM8, and ADAM17/TACE (IC₅₀ = 3, 4, 20, 6, 4, 2.08, 51.3, and 19 nM, respectively), by targeting both the substrate binding site and the active-site Zn²⁺, while being much less potent toward ACE (Angiotensin Converting Enzyme) or α-secretase (IC₅₀ = 1.6 and 3.3 µM, respectively). Batimastat is widely used in studying the involvement of MMPs in cancinogenesis and non-cancer pathological processes both in cultures in vitro and in animals in vivo. Also available as a 25 mM solution in DMSO (Cat. No. 508408).

A Marimastat (Cat. No. 444289) type of peptidyl hydroxamate-based inhibitor that potently inhibits a broad-spectrum of metalloproteinases, including MMP-1, MMP-2, MMP-3/stromelysin, MMP-7/matrilysin, MMP-9, ΔMT1 (MMP-14 without TM domain), ADAM8, and ADAM17/TACE (IC₅₀ = 3, 4, 20, 6, 4, 2.08, 51.3, and 19 nM, respectively), by targeting both the substrate binding site and the active-site Zn²⁺, while being much less potent toward ACE (Angiotensin Converting Enzyme) or α-secretase (IC₅₀ = 1.6 and 3.3 µM, respectively). Batimastat is widely used in studying the involvement of MMPs in cancinogenesis and non-cancer pathological processes both in cultures in vitro and in animals in vivo.

Embalagem

Packaged under inert gas

Advertência

Toxicity: Standard Handling (A)

Reconstituição

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Outras notas

Schlomann, U., et al. 2002. J. Biol. Chem.277, 48210.
Whittaker, M., et al. 1999. Chem. Rev.99, 2735.
Parvathy, S., et al. 1998. Biochemistry37, 1680.
Parvathy, S., et al. 1998. FEBS Lett.431, 63.
Yamamoto, M., et al. 1998. J. Med. Chem.41, 1209.
Moss, M.L., et al. 1997. Nature385, 733.
Eccles, S.A., et al. 1996. Cancer Res.56, 2815.
Brown, P.D. 1995. Advan. Enzyme Regul.35, 293.
Wang, X., et al. 1994. Cancer Res.54, 4726.
Davies, B., et al. 1993. Cancer Res.53, 2087.

Informações legais

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informações de segurança

• Código de classe de armazenamento: 11 - Combustible Solids
• Classe de risco de água (WGK): WGK 3
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable